Drug Pipeline · Obesity Medicine ·
By The RX Index Editorial Team · · Affiliate disclosure · Editorial standards
What Is CagriSema?
CagriSema is a once-weekly investigational injection that combines two medications — semaglutide (the active ingredient in Wegovy and Ozempic) and cagrilintide (a new amylin-based drug) — into a single shot. It’s being developed by Novo Nordisk to treat obesity and type 2 diabetes by activating two appetite pathways instead of one.
In the most-watched trial, people taking CagriSema lost an average of 22.7% of their body weight over 68 weeks — significantly more than semaglutide (Wegovy) alone. But CagriSema is not FDA-approved, it is not commercially available outside clinical trials, and it did not match Zepbound (tirzepatide) in a head-to-head comparison. Novo Nordisk filed for U.S. approval in , with an FDA decision anticipated by late 2026.
If you’re searching this because you’re considering weight management treatment — that timeline matters. Multiple FDA-approved GLP-1 medications are available right now, and waiting for a drug whose price, label, and exact launch date are still unknown is a real trade-off.
Need a medication you can actually start now? Take our free 60-second matching quiz — we’ll show you the GLP-1 programs you can access today, not pipeline drugs you’d be waiting on.
Find My GLP-1 Path — Free 60-Second Quiz →
CagriSema at a Glance
| What we know as of | |
|---|---|
| What it is | Once-weekly injection: cagrilintide 2.4 mg + semaglutide 2.4 mg |
| Manufacturer | Novo Nordisk (the company behind Wegovy and Ozempic) |
| FDA status | Not approved in the U.S. or Europe. NDA filed Dec 18, 2025. Decision anticipated late 2026. |
| Best weight loss result | 22.7% body weight at 68 weeks (REDEFINE 1, full adherence) |
| Beat semaglutide alone? | Yes — by 6.6 points in REDEFINE 1 and 4.0 points in REIMAGINE 2 |
| Beat tirzepatide (Zepbound)? | No — missed non-inferiority in REDEFINE 4 head-to-head |
| Available now? | No. Not commercially available or prescribable outside clinical trials. |
How Does CagriSema Work?
CagriSema works by activating two separate hormonal pathways that regulate hunger and fullness — GLP-1 and amylin — in a single weekly injection. Current GLP-1 medications like Wegovy target only one of these pathways. Combining both produces stronger appetite suppression and greater weight loss than semaglutide alone, based on data from the REDEFINE 1 trial (NEJM, 2025).
Your body uses multiple signals to tell your brain you’re full. Semaglutide mimics a gut hormone called GLP-1, which reduces appetite, slows digestion, and helps regulate blood sugar. Cagrilintide mimics a different hormone called amylin, which is released by the pancreas after meals and signals fullness through different neural pathways than GLP-1.
When both signals fire at the same time, satiety is stronger — you feel full sooner and stay satisfied longer.
What’s Different About Combining Amylin + GLP-1
Why not just use more semaglutide? The answer is that the two pathways do different things.
In an animal study published in Nature Metabolism (2025), researchers found that CagriSema didn’t just reduce how much rats ate — it also blunted the metabolic slowdown that normally accompanies weight loss. About one-third of CagriSema’s weight-loss effect came from preserving energy expenditure, not just cutting food intake. Whether that translates to humans hasn’t been confirmed, but it’s a mechanistic advantage worth tracking.
CagriSema vs. Tirzepatide: Two Different Combination Strategies
CagriSema
A fixed-dose combination of two separate drugs in one injection: semaglutide (GLP-1 receptor agonist) + cagrilintide (amylin receptor agonist). Targets the GLP-1 and amylin pathways.
Tirzepatide (Zepbound / Mounjaro)
A single dual-agonist molecule that activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. FDA-approved and available now.
Is CagriSema FDA Approved?
No — as of , CagriSema is not approved by the U.S. FDA or the European Medicines Agency.
It cannot be prescribed at any pharmacy.
Novo Nordisk filed a New Drug Application (NDA) with the FDA on , seeking approval for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbid condition. Novo Nordisk has stated that an FDA decision is anticipated by late 2026. No exact PDUFA target date has been publicly confirmed. Commercial launch timing, real-world pricing, and insurance coverage are not yet announced.
Source: Novo Nordisk press release, ; PR Newswire.
If You See CagriSema Sold Online Right Now, Stop
Any website claiming to sell CagriSema as a finished retail product today is not selling legitimate CagriSema. The drug has not been manufactured for commercial distribution. The FDA has explicitly stated that cagrilintide cannot be used in compounding under federal law, and the agency has issued multiple consumer warnings about unapproved GLP-1 products sold online. If you’re shopping for GLP-1 treatment, stick with FDA-approved medications through licensed channels.
If you need treatment now and don’t want to wait for FDA approval, we can show you what’s actually available.
Take Our Free 60-Second Matching Quiz →Can You Get CagriSema Through a Clinical Trial?
Possibly. Several REDEFINE program trials are still recruiting participants in the United States and other countries. If you meet eligibility criteria — typically obesity (BMI ≥30) or overweight with comorbidities, and willingness to attend trial visits — clinical trial enrollment is the only legitimate way to receive CagriSema right now.
Trial participation is free, and you receive medical oversight as part of the protocol. The trade-offs: you may receive a placebo or comparator drug instead of CagriSema, you have less control over your treatment, and trial sites may not be near you.
You can search active CagriSema trials at ClinicalTrials.gov by searching “CagriSema” or “cagrilintide semaglutide.” Major active programs include REDEFINE 8, REDEFINE 11, and the upcoming high-dose CagriSema Phase 3 trial set to begin in the second half of 2026.
Source: Novo Nordisk Annual Report 2025; ClinicalTrials.gov.
Why Is Everyone Talking About CagriSema Right Now?
CagriSema sits at the center of the biggest question in obesity medicine: what comes after Wegovy and Zepbound? The search interest spike comes from a series of major events in a short window — most notably a sequence in February 2026 where CagriSema beat semaglutide and then lost to tirzepatide within three weeks.
The 2025–2026 Timeline That Explains the Buzz
| Date | What happened |
|---|---|
| REDEFINE 1 results announced: 22.7% weight loss, beating semaglutide alone | |
| REDEFINE 2 results: 15.7% weight loss in type 2 diabetes patients | |
| REDEFINE 1 and 2 published in the New England Journal of Medicine | |
| Novo Nordisk files NDA with the FDA | |
| REIMAGINE 2 results: CagriSema beats semaglutide head-to-head in type 2 diabetes | |
| REDEFINE 4 results: CagriSema LOSES to tirzepatide (Zepbound) head-to-head | |
| Late 2026 | FDA decision anticipated |
| H2 2026 | High-dose CagriSema (2.4 mg / 7.2 mg) Phase 3 trial set to begin |
| H1 2027 | REDEFINE 11 data expected |
Sources: Novo Nordisk press releases (Dec 2024, March 2025, Dec 2025, Feb 2026); NEJM (June 2025); Novo Nordisk Annual Report 2025.
What Do the Clinical Trials Actually Show?
CagriSema produces meaningful weight loss — more than any single-agent semaglutide product on the market today. But it’s not “best in class” by current head-to-head evidence, because it didn’t match tirzepatide (Zepbound) in a direct comparison. Below is every major CagriSema trial in one structured view.
The RX Index CagriSema Trial Tracker
| Trial | Who was studied | Duration | Weight loss (full adherence) | Weight loss (all participants) | Comparator result | Primary endpoint met? |
|---|---|---|---|---|---|---|
| REDEFINE 1 | 3,417 adults with obesity, no diabetes | 68 wks | 22.7% | 20.4% | Semaglutide alone: 16.1% | Placebo: 2.3% | ✅ Yes — superior to placebo |
| REDEFINE 2 | 1,206 adults with T2D + obesity | 68 wks | 15.7% | 13.7% | Placebo: 3.1% | ✅ Yes — superior to placebo |
| REDEFINE 4 | 809 adults with obesity | 84 wks | 23.0% | 20.2% | Tirzepatide 15 mg: 25.5% / 23.6% | ❌ No — missed non-inferiority vs tirzepatide |
| REIMAGINE 2 | Adults with T2D | 68 wks | 14.2% | — | Semaglutide 2.4 mg: 10.2% | ✅ Yes — superior to semaglutide on weight + HbA1c |
| REIMAGINE (Phase 2) | 92 adults with T2D | 32 wks | 15.6% | — | Semaglutide: 5.1% | Cagrilintide: 8.1% | N/A (Phase 2) |
Sources: Novo Nordisk press releases (Dec 2024, March 2025, Feb 2026); NEJM publications (June 2025); Lancet (Aug 2023). The “full adherence” column reflects the trial-product estimand (idealized adherence). The “all participants” column reflects the treatment-policy estimand (including patients who stopped treatment).
22.7%
The headline. REDEFINE 1 participants who stayed on CagriSema lost nearly a quarter of their body weight on average. For someone who weighs 240 lbs, that’s roughly 54 lbs. More than 40% of participants hit 25% weight loss or greater.
25.5%
What tirzepatide (Zepbound) achieved in REDEFINE 4. CagriSema ’s 23.0% wasn’t enough to demonstrate statistical equivalence. This is the number that caused Novo Nordisk’s stock to drop ~15%.
REDEFINE 4: The Honest Assessment
In , Novo Nordisk released results from REDEFINE 4 — an open-label, head-to-head comparison of CagriSema versus tirzepatide 15 mg in 809 adults with obesity. After 84 weeks:
Tirzepatide (Zepbound)
25.5%
full adherence
23.6%
regardless of dropout
CagriSema
23.0%
full adherence
20.2%
regardless of dropout
Our take:
CagriSema is not a failure. Twenty to twenty-three percent weight loss is a meaningful clinical result — better than any single-agent semaglutide product currently on the market. But it isn’t the “Zepbound killer” the market was hoping for. A few percentage points of additional weight loss may or may not change long-term outcomes for any individual patient — that’s a question for your clinician.
Important caveat: REDEFINE 4 was open-label (both patients and doctors knew which drug they received). Novo Nordisk has a high-dose CagriSema formulation (cagrilintide 2.4 mg + semaglutide 7.2 mg) entering Phase 3 in H2 2026, which could close the gap.
What’s Still Coming
- • REDEFINE 3: Cardiovascular outcomes trial in 7,000 patients — in progress
- • REDEFINE 8: 104-week durability and weight-maintenance study
- • REDEFINE 11: Full weight-loss potential study — data expected
- • High-dose CagriSema (2.4 mg / 7.2 mg): Phase 3 set for
Source: Novo Nordisk Annual Report 2025; Novo Nordisk investor communications.
How Does CagriSema Compare to Wegovy, Zepbound, and Other GLP-1s?
CagriSema produces meaningfully more weight loss than semaglutide alone (Wegovy) but modestly less than tirzepatide (Zepbound) based on available head-to-head data. Critical context: CagriSema is not yet approved, while the others are available now.
GLP-1 Weight Loss Comparison — CagriSema vs. Currently Available Medications
| Medication | How it works | Weight loss in pivotal trial | FDA status | Available now? |
|---|---|---|---|---|
| CagriSema | GLP-1 + amylin (combination) | 22.7% — REDEFINE 1 (68 wks) | Under FDA review | No |
| Zepbound (tirzepatide) | Single dual-agonist (GLP-1 + GIP) | 22.5% — SURMOUNT-1 (72 wks) / 25.5% — REDEFINE 4 (84 wks) | Approved for weight loss | Yes ✅ |
| Wegovy (semaglutide 2.4 mg) | GLP-1 | 14.9% — STEP 1 (68 wks) / 16.1% — REDEFINE 1 (68 wks) | Approved for weight loss | Yes ✅ |
| Mounjaro (tirzepatide) | Single dual-agonist (GLP-1 + GIP) | ~22.5% (highest dose, SURMOUNT-1) | Approved for diabetes | Yes ✅ |
| Saxenda (liraglutide) | GLP-1 | ~8% — SCALE Obesity (56 wks) | Approved for weight loss | Yes ✅ |
Sources: REDEFINE 1 (NEJM, 2025); REDEFINE 4 (Novo Nordisk, Feb 2026); SURMOUNT-1 (NEJM, 2022); STEP 1 (NEJM, 2021). Cross-trial comparisons have inherent limitations — different populations, designs, and durations. These figures provide directional context, not direct equivalence.
Head-to-Head vs. Semaglutide: CagriSema Wins
In REDEFINE 1: 22.7% vs 16.1% — 6.6 percentage points advantage. In REIMAGINE 2 (T2D): 14.2% vs 10.2% — 4.0 percentage points advantage. Both trials showed greater HbA1c reductions too.
Head-to-Head vs. Tirzepatide: CagriSema Falls Short
In REDEFINE 4: 23.0% vs 25.5% — a 2.5 percentage-point gap prevented CagriSema from demonstrating non-inferiority. On current data, Zepbound wins this matchup.
If your only priority is the strongest currently published head-to-head obesity result, tirzepatide (Zepbound) is the better evidence-based choice today — and that medication is available right now through licensed telehealth providers.
Explore Tirzepatide and Wegovy Options Available Now on Ro →What Are the Side Effects of CagriSema?
The most common side effects are gastrointestinal — nausea, constipation, and vomiting — consistent with both the GLP-1 and amylin drug classes. Because CagriSema combines two active drugs, GI side effect rates are higher than with semaglutide alone.
CagriSema Side Effects from REDEFINE 1
| Side effect | CagriSema rate | Context |
|---|---|---|
| Any GI event | 79.6% | vs. 39.9% for placebo |
| Nausea | 55.0% | Most common; typically peaks during dose titration |
| Constipation | 30.7% | Manageable for most |
| Vomiting | 26.1% | Notably higher than semaglutide alone |
| Discontinued due to adverse events | 5.9% | Suggesting most patients tolerated treatment |
Sources: Novo Nordisk REDEFINE 1 press release, ; NEJM publication, June 2025.
Important diabetes-specific safety note
In REDEFINE 2 (the diabetes population), GI events occurred in 72.5% of CagriSema patients, and 8.4% discontinued due to adverse events. Level 2 hypoglycemia occurred in 6.0% of CagriSema participants and level 3 hypoglycemia in 0.2%, primarily among patients also taking sulfonylureas. This is consistent with the broader GLP-1 class and worth knowing if you have type 2 diabetes and currently take a sulfonylurea.
The honest trade-off
Higher GI side effects are the cost of stronger weight loss. For most participants, these effects were mild-to-moderate, peaked during the dose-escalation phase, and decreased over time. But if you already struggle with nausea on a current GLP-1, CagriSema may be more difficult to tolerate — not easier.
What Isn’t Known Yet
- •Final FDA labeling and boxed warnings — currently approved semaglutide products carry warnings about thyroid C-cell tumors and pancreatitis
- •Long-term cardiovascular outcomes — REDEFINE 3 is studying this in 7,000 patients but results aren't available yet
- •Real-world pricing — not announced
- •Long-term tolerability beyond 84 weeks — the longest published data is from REDEFINE 4
- •Insurance coverage and formulary positioning — completely unknown
How Much Will CagriSema Cost?
Novo Nordisk has not announced pricing for CagriSema. To set realistic expectations, here are current verified U.S. prices for comparable GLP-1 medications as of :
| Medication | List price (per month) | Cash-pay options |
|---|---|---|
| Wegovy (semaglutide 2.4 mg) | $1,349.02 | Manufacturer savings programs available; varies by insurance |
| Zepbound (tirzepatide) | Up to $1,086.37 | LillyDirect self-pay vials: $299 / $399 / $449 by dose tier |
| Ozempic (semaglutide) | $1,027.51 | Insurance-dependent |
Sources: NovoCare (Wegovy and Ozempic list prices, ); LillyDirect (Zepbound list and self-pay pricing, ).
Given that CagriSema combines two active ingredients and is being positioned as a next-generation product, it will likely be priced at or above current GLP-1 medications. We’ll update this page when official pricing is announced.
A note on compounded GLP-1 options
Some readers will encounter compounded semaglutide or tirzepatide marketed as a lower-cost alternative. Important context: compounded GLP-1 medications are NOT FDA-approved. The FDA has not reviewed compounded semaglutide or tirzepatide for safety, effectiveness, or quality, and has issued warning letters to multiple telehealth companies regarding compounded GLP-1 marketing. Compounded products should not be confused with FDA-approved branded medications. Verify the prescribing provider, the dispensing pharmacy, and the medication source before committing.
Should You Wait for CagriSema or Start Treatment Now?
For most people who need weight management treatment, waiting for CagriSema is not the right strategy. The drug is at minimum many months from reaching most patients through standard channels — and pricing, label, and exact launch timing are still unknown. Multiple FDA-approved options producing 16–25% weight loss are available today. Starting now doesn’t prevent you from switching later if CagriSema proves to be the better fit.
The RX Index “Wait or Start” Decision Framework
| Your situation | Our recommendation | Why |
|---|---|---|
| Not on any GLP-1 and need to lose weight | Don't wait | Months of progress is too much to leave on the table. Start with an FDA-approved option now. |
| On Wegovy/semaglutide and want more results | Consider switching now, not waiting | Zepbound (tirzepatide) is available today and showed more weight loss than CagriSema in head-to-head trials. |
| On Zepbound/tirzepatide and doing well | No reason to switch | CagriSema did not match tirzepatide in REDEFINE 4. Stay with what's working. |
| Have type 2 diabetes and prioritize A1c | Worth tracking — but don't delay treatment | CagriSema showed strong diabetes results. But Mounjaro and Ozempic are approved for T2D and work well now. |
| Can't tolerate GLP-1 side effects | CagriSema is unlikely to help | GI side effect rates are higher with CagriSema than with semaglutide alone. |
| Cost is your biggest barrier | Don't wait for a premium-priced drug | Look at FDA-approved self-pay programs like LillyDirect ($299–$449/month for Zepbound vials). |
| Just researching the pipeline | Bookmark this page and check back | We update as new data publishes. The next major milestone is the FDA decision (anticipated late 2026). |
The bottom line: every month you defer treatment is progress you could be making right now. CagriSema may become a valuable option in 2027 — but the medication you start today begins working this week.
Not sure which GLP-1 program fits your situation? Answer a few questions about your goals, insurance, and timeline — we’ll match you to FDA-approved options you can actually access now.
Take the Free 60-Second Matching Quiz →What We Actually Verified for This Page
Primary sources reviewed
- •Novo Nordisk official press releases (Dec 20, 2024; March 10, 2025; Dec 18, 2025; Feb 2, 2026; Feb 23, 2026)
- •New England Journal of Medicine publications of REDEFINE 1 and REDEFINE 2 (June 2025)
- •The Lancet Phase 2 REIMAGINE trial publication (August 2023)
- •FDA NDA filing announcement via PR Newswire (December 18, 2025)
- •Nature Metabolism CagriSema mechanism study (2025)
- •American Diabetes Association presentation of REDEFINE program data
- •FDA consumer guidance on unapproved GLP-1 products
- •NovoCare and LillyDirect for April 2026 list and self-pay pricing
- •Novo Nordisk Annual Report 2025 for pipeline trial details
What we could NOT independently verify
- •Exact PDUFA target date (not publicly announced)
- •CagriSema commercial launch timing (not announced)
- •CagriSema pricing (not announced)
- •Insurance formulary positioning (not determined)
- •Final FDA label, including any boxed warnings (pending FDA decision)
Why this page exists: The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. We built this page because “what is CagriSema” deserves a complete, honest answer — not a sales pitch for a drug you can’t get yet, and not a thin explainer that leaves you opening more tabs.
Frequently Asked Questions
Is CagriSema FDA approved?
No. As of April 2026, CagriSema is not approved by the U.S. FDA or the European Medicines Agency. Novo Nordisk filed for U.S. approval on December 18, 2025. A decision is anticipated by late 2026.
When will CagriSema be available?
If the FDA approves CagriSema on the anticipated late-2026 timeline, commercial availability would likely follow in the months after approval. Specific launch timing has not been announced, and insurance coverage typically lags brand launches.
What is CagriSema made of?
CagriSema is a fixed-dose combination of cagrilintide 2.4 mg (a long-acting amylin analog) and semaglutide 2.4 mg (a GLP-1 receptor agonist), delivered as a single once-weekly subcutaneous injection.
How much weight loss has CagriSema shown?
In REDEFINE 1 (adults with obesity, no diabetes), CagriSema produced 22.7% weight loss at 68 weeks among adherent participants and 20.4% across all participants. In REDEFINE 2 (adults with type 2 diabetes), the figures were 15.7% and 13.7%, respectively.
Is CagriSema better than Wegovy?
On clinical trial weight loss, yes — CagriSema produced 6.6 percentage points more weight loss than semaglutide 2.4 mg (Wegovy's active ingredient) in REDEFINE 1, and 4.0 points more in REIMAGINE 2. However, Wegovy is FDA-approved and available now; CagriSema is not.
Is CagriSema better than Zepbound?
Not based on the current head-to-head data. In REDEFINE 4, tirzepatide (Zepbound) achieved 25.5% weight loss versus CagriSema's 23.0% among adherent participants. CagriSema did not meet the statistical threshold for non-inferiority.
What are the side effects of CagriSema?
The most common are gastrointestinal: nausea (55.0%), constipation (30.7%), and vomiting (26.1%) in REDEFINE 1. Most were mild-to-moderate and decreased over time. Approximately 5.9% of REDEFINE 1 participants discontinued due to adverse events.
How much will CagriSema cost?
Pricing has not been announced. Comparable GLP-1 medications currently range from $1,027 to $1,349 per month at U.S. list price, with self-pay and savings programs varying by manufacturer.
Can you buy CagriSema online right now?
No. The drug has not been manufactured for commercial distribution. The FDA has stated that cagrilintide cannot be used in compounding, and any website claiming to sell finished CagriSema as a retail product is not legitimate.
Is CagriSema for weight loss, type 2 diabetes, or both?
It's being studied for both. The current FDA application is for chronic weight management in adults with obesity or overweight. Separate programs (REIMAGINE) study CagriSema for type 2 diabetes; a diabetes-specific FDA application has not been filed.
Can I get CagriSema through a clinical trial?
Possibly. Several REDEFINE trials are still recruiting. Search ClinicalTrials.gov for "CagriSema" or "cagrilintide semaglutide" to find active sites and eligibility criteria.
What Can You Do Right Now?
CagriSema may be available in 2027. Your goals don’t have to wait that long.
Several FDA-approved GLP-1 medications — including semaglutide (Wegovy) and tirzepatide (Zepbound) — are available through licensed telehealth providers right now, with self-pay options that can make them more affordable than insurance might suggest. The right choice depends on your health profile, insurance, budget, and state.
Find My GLP-1 Path — Free 60-Second Quiz →Browse Available GLP-1 Programs on Ro →Related guides
- Oral GLP-1 Providers That Take HSA or FSA (2026) — Foundayo + Wegovy pill compared
- Wegovy Providers That Take HSA or FSA — verified payment paths
- GLP-1 Copay Assistance Programs 2026 — savings cards, PAPs, Medicare Bridge
- Does Medicare Cover Wegovy? — 2026 rules and the July GLP-1 Bridge
- Can You Use HSA or FSA for Ozempic? — IRS rules and LMN guide
- Best GLP-1 Telehealth Providers Compared for 2026
By The RX Index Editorial Team — a pricing intelligence and comparison resource for GLP-1 telehealth providers. This page was produced by reviewing official Novo Nordisk press releases, NEJM publications, FDA guidance documents, and NovoCare and LillyDirect pricing pages. All clinical data is from published trial results or official press releases — not from secondary summaries. This page is for informational purposes only and does not constitute medical advice.